Alexion Pharmaceuticals Inc (ALXN): Carsten Thiel , EVP, Chief Commercial Officer of Alexion Pharmaceuticals Inc sold 3,225 shares on Sep 12, 2016. The Insider selling transaction was reported by the company on Sep 14, 2016 to the Securities and Exchange Commission. The shares were sold at $126.60 per share for a total value of $414,945.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 9, 2016, Edward Miller (SVP, Chief Compliance Officer) sold 367 shares at $128.32 per share price.On Sep 8, 2016, Carsten Thiel (EVP, Chief Commercial Officer) sold 1,000 shares at $125.94 per share price.Also, On Sep 2, 2016, Julie O’neill (EVP. Global Operations) sold 650 shares at $126.29 per share price.On Sep 1, 2016, Clare Carmichael (EVP, Chief HR Officer) sold 1,000 shares at $127.76 per share price.
Alexion Pharmaceuticals: On Monday, Sep 12, 2016 heightened volatility was witnessed in Alexion Pharmaceuticals which led to swings in the share price. The shares opened for trading at $124.2 and hit $129.52 on the upside , eventually ending the session at $129.29, with a gain of 3.50% or 4.37 points. The heightened volatility saw the trading volume jump to 1,227,650 shares. The 52-week high of the share price is $193.45 and the company has a market cap of $28,993 M . The 52-week low of the share price is at $110.56.
Company has been under the radar of several Street Analysts.Alexion Pharmaceuticals is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 182 from a previous price target of $195 . The Rating was issued on Jul 29, 2016.Alexion Pharmaceuticals is Reiterated by Barclays to Equal Weight while Lowering the Price Target of the company shares to $ 150 from a previous price target of $165 . The Rating was issued on Jul 29, 2016.Alexion Pharmaceuticals is Initiated by RBC Capital Mkts to Outperform and the brokerage firm has set the Price Target at $188. The Rating was issued on Jul 13, 2016.Alexion Pharmaceuticals is Reiterated by SunTrust to Buy while Lowering the Price Target of the company shares to $ 197 from a previous price target of $220 . The Rating was issued on Jul 13, 2016.Alexion Pharmaceuticals is Upgraded by Credit Suisse to Outperform while Lowering the Price Target of the company shares to $ 165 from a previous price target of $186 . Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Jul 11, 2016.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.